Combination immunotherapy shrank a variety of metastatic gastrointestinal cancers
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-Jun-2025 19:09 ET (1-Jun-2025 23:09 GMT/UTC)
A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers, according to results of a clinical trial led by researchers at the National Institutes of Health (NIH). The findings, published April 1, 2025 in Nature Medicine, offer hope that this therapy could be used to treat a variety of solid tumors, which has so far eluded researchers developing cell-based therapies.
In a prospective cohort study of more than 85,000 adults in the United Kingdom, researchers at the National Institutes of Health (NIH) and University of Oxford found that individuals who engaged in light- and moderate-to-vigorous-intensity daily physical activity had a lower risk of cancer than individuals who were more sedentary. The findings, published March 26, 2025, in British Journal of Sports Medicine, are among the first to evaluate the cancer risk reduction associated with light-intensity activities such as doing errands and performing household chores.